A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum

European Journal of Cancer

Volumn 34, Issue 8, 1998, Pages 1208-1212

  Lorusso, V ^a   Pollera, C F ^b   Antimi, M ^c   Luporini, G ^d   Gridelli, C ^e   Frassineti, G L ^f   Oliva, C ^g   Pacini, M ^g   De Lena, M ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d SAN CARLO BORROMEO HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f MORGAGNI PIERANTONI HOSPITAL   (Italy)

^g Eli Lilly Italia   (Italy)

Author keywords

Cisplatin pretreated patients; Gemcitabine; Treatment outcome; Urinary tract carcinoma

Indexed keywords

ANTIMETABOLITE; GEMCITABINE; PLATINUM; PYRIMIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFLUENZA, HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 0032127772     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00030-6     Document Type: Article

References (24)

1. 1. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (difluor-2′-deoxy-citidine). Cancer Res 1990, 50, 4417-4422.
2. 2. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9, 491-498.
3. 3. Gatzeimer U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996, 32A, 243-248.
4. 4. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine in previously treated ovarian cancer patients. J Natl Cancer Inst 1994, 86, 1530-1533.
5. 5. Carmichael J, Passinger K, Philip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995, 13(11), 2731-2736.
6. 6. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994, 5, 182-184.
7. 7. Carmichael J, Fink U, Russel RCJ, et al. Phase III study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996, 73, 101-105.
8. 8. Huang P, Chung S, Hertel LW, Grindey JB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51, 6110-6117.
9. 9. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′-2′-difluorodeoxycytidine and 1-D-arabinofuranosylcytosine. Cancer Res 1988, 48, 4024-4031.
10. 10. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992, 52, 533-539.
11. 11. O'Rourke TJ, Brown TD, Havlin K, et al. Phase I clinical trial of gemcitabine as an intravenous bolus for 5 consecutive days. Eur J Cancer 1994, 30, 417-418.
12. 12. Poplin E, Corbett T, Flaherty L, et al. Difluorodeoxycytidine (dFdC)-gemcitabine: a phase I study. Inv New Dr 1992, 10, 165-170.
13. 13. Tanis B, Clavel M, Guastalla J, et al. Phase I study of gemcitabine (difluorodeoxycytidine dFdC (LY188011)) administered in a two weekly schedule. Proc Am Assoc Cancer Res 1990, 31, 1239.
14. 14. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organisation, 1979.
15. 15. Stenberg CN, Yagoda A, Sher HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 1989, 64, 2448-2458.
16. 16. Roth BJ. Palliative chemotherapy in advanced bladder cancer. Semin Oncol 1995, 22(Suppl. 3), 10-15.
17. 17. Tannock I, Gospodarowicz M, Connolly J, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 1989, 142, 289-292.
18. 18. Dismopulos MA, Finn L, Logothetis CJ, et al. Pattern of failure and survival of patients with metastatic urothelial tumours relapsing after cisplatin based chemotherapy. J Urol 1994, 151, 598-601.
19. 19. Witte RS, Elson P, Bono B, et al. Eastern Co-operative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997, 15, 589-593.
20. 20. Einhorn LM, Roth BJ, Ansari R, et al. Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 1994, 12, 2271-2276.
21. 21. Roth BJ. Preliminary experience with paclitaxel in advanced bladder cancer. Semin Oncol 1995, 22(3 Suppl. 6), 1-5.
22. 22. Igawa M, Ohkuchi T, Ueki T, et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990, 144, 662-665.
23. 23. Stadler W, Kuzel T, Raghavan D, Levine, E, Vogelzang N, Dorr A. A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 1995, 14, 241 (abstract 638).
24. 24. Moore MJ, Tannock I, Ernst S, Huan S, Murray N. Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 1996, 15, 250 (abstract 637).